Chelsea Northera gets 2nd chance at FDA; shares up
This article was originally published in Scrip
Executive Summary
Shares of Chelsea Therapeutics got a 6.1% boost in morning trading on 17 July on word the FDA had quickly accepted the company's resubmission of its new drug application (NDA) for Northera (droxidopa), an orally active synthetic precursor of norepinephrine, as a treatment for symptomatic neurogenic orthostatic hypotension (NOH), a chronic neurogenic disorder resulting from deficient release of norepinephrine, the neurotransmitter used by autonomic nerves to send signals to the blood vessels and the heart.